Who are Judo Bio's investors?

Judo Bio's investors include Atlas Venture, Alexandria Venture Investments, Digitalis Ventures, Droia Ventures, Euclidean Capital.

Where is Judo Bio headquartered?

Judo Bio is headquartered in Cambridge, Massachusetts, United States.

What industry is Judo Bio in?

Judo Bio operates in Biotech, Healthcare.

Judo Bio

Breaking through to the kidney

Cambridge, United States · Founded 2022

Biotech

Healthcare

Headquarters: Cambridge, Massachusetts
Employees: 11–50
Founded: 2022
Business Model: B2B

Website: judo.bio
Last Round: SeedOct 2024
Rounds: 2

About

Judo Bio is a Cambridge, Massachusetts-based biotechnology company pioneering oligonucleotide medicines delivered to the kidney, opening new treatment pathways for systemic and renal diseases. The company's proprietary STRIKE platform harnesses a natural, endogenous receptor-mediated mechanism to target ligand-siRNA conjugate drugs to specific kidney cell types, enabling gene silencing of disease-modifying targets. Judo Bio's initial drug programs address both systemic diseases with renal manifestations and primary kidney diseases where the organ has historically been difficult to reach with genetic medicines. The company launched in October 2024 with $100 million in financing and is backed by Atlas Venture, Digitalis Ventures, The Column Group, and Droia Ventures.

Summary

Judo Bio is a Biotech company based in Cambridge, United States, founded in 2022. Its most recent funding was a Seed round in Oct 2024. Investors include Atlas Venture, Alexandria Venture Investments and Digitalis Ventures.